School of Medicine
Showing 501-600 of 1,056 Results
-
Vinh Lam
Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioDr. Vinh Lam is a Clinical Assistant Professor in the Department of Medicine, Division of Primary Care and Population health. He earned his MD from the David Geffen School of Medicine at UCLA and chose to stay in Los Angeles to complete his family medicine residency training at UCLA. During his training, Dr. Lam developed a strong interest in teaching and medical education through his involvement with resident education and the graduate medical education committee. He also spent 1 year as a resident informaticist where he also became very interested in informatics, medical technology, and innovative solutions to improving patient health outcomes and decreasing physician burnout. Dr. Lam enjoys caring for patients of all ages from pediatrics to geriatrics, performing office-based procedures, and prioritizing preventative care.
Outside of medicine, Dr. Lam loves to travel with his family, dabbles in photography and videography, and enjoys attempting to recreate meals he has had while traveling with his wife. -
Curtis Langlotz
Professor of Radiology (Thoracic Imaging), of Medicine (Biomedical Informatics Research), of Biomedical Data Science and Senior Fellow at the Stanford Institute for HAI
Current Research and Scholarly InterestsI am interested in the use of deep neural networks and other machine learning technologies to help radiologists detect disease and eliminate diagnostic errors. My laboratory is developing deep neural networks that detect and classify disease on medical images. We also develop natural language processing methods that use the narrative radiology report to create large annotated image training sets for supervised machine learning experiments.
-
Benjamin Laniakea
Clinical Associate Professor, Medicine - Primary Care and Population Health
BioDr. Benji Laniakea serves as the chief of the Stanford LGBTQ+ Adult Clinical Program, which offers comprehensive and tailored healthcare for the LGBTQ+ patient population for patients of all ages, sexualities, and gender identities. They also serve as the theme lead for the Sex, Gender, Sexuality, and Sexual Function curriculum at the Stanford School of Medicine for which they received the Arthur L. Bloomfield Award, and have the honor of advising the American Medical Association on LGBTQ+ Health.
-
Tobias Lanz
Assistant Professor of Medicine (Immunology and Rheumatology)
BioTobias Lanz, MD is an Assistant Professor at the Institute for Immunity, Transplantation, and Infection and the Division of Immunology and Rheumatology at Stanford. His research focuses on B cell biology in neuroimmunological diseases and rheumatic diseases with neurological manifestations. He uses high-throughput screening technologies, and methods from structural and cell biology to identify new autoantigens and to understand how certain self-reactive B cells escape tolerance mechanisms. He is particularly interested in molecular mechanisms that explain the association between Epstein Barr Virus (EBV) and autoimmunity.
Tobias went to medical school at the Eberhard Karls University in Tübingen, Germany and at the University College of London. He wrote his MD thesis at Dr. Michael Platten's laboratory at the Hertie Institute for Clinical Brain Research in Tübingen, Germany before joining Dr. Lawrence Steinman’s neuroimmunological laboratory at Stanford as a research scholar. After medical school he pursued his scientific and clinical training at the German Cancer Research Center (DKFZ) and the Department of Neurology at the University Hospital in Heidelberg, Germany. In 2015 he joined Dr. William Robinson’s lab at Stanford, where he investigated environmental triggers of autoimmunity, including viruses and milk consumption. In his most recent work, he characterized the B cell repertoire in the spinal fluid of patients with multiple sclerosis (MS) and identified molecular mimicry between EBV EBNA1 and the glial cellular adhesion molecule GlialCAM as a driver of neuroinflammation (Lanz et al., Nature, 2022). His long term objective is to leverage these newly discovered mechanistic insights to develop next-generation biomarkers and therapeutics for autoimmune diseases. -
Alice A. Lee
Instructor, Medicine - Gastroenterology & Hepatology
Current Research and Scholarly InterestsDr. Lee's research focuses on the early detection of pancreatic cancer, including the investigation of risk factors for pancreatic cancer and biomarkers to detect early cancer.
-
David Lee, MD
Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly Interests1. Novel treatments and devices for the treatment of valvular disease
2. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy
3. Novel approaches to coronary revascularization
4. Closure devices for atrial septal defects and patent foramen ovale
5. Novel treatments for hypertension -
Jennifer Lee
Professor of Medicine (Endocrinology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsI am a clinical scientist (PhD epidemiology), endocrinologist, and CMO at VAPA Cooperative Studies Program Coordinating Center. My group does pattern and prediction mapping along the life-course of interventions/outcomes and how healthcare system can positively impact health longitudinally. We use novel molecular epi, 'big' data like EHRs using multiple designs/methods/technologies. These interests cut across multiple complex chronic diseases and lifespan.
https://med.stanford.edu/jleelab.html -
Seolhyun Lee, MD
Clinical Assistant Professor, Medicine - Nephrology
BioDr. Lee is a nephrologist and Clinical Assistant Professor in the Nephrology Division of the Stanford Department of Medicine.
He delivers expert, compassionate kidney care personalized to each patient he serves. Dr. Lee is committed to improving both the health and quality of life of his patients.
His work scholarship has appeared in the Journal of the American Society of Nephrology, Kidney Week, and Blood Purification.
Dr. Lee has received honors and awards including the prestigious Ben J. Lipps Research Fellowship from the American Society of Nephrology. The program funds original research projects by nephrology fellows. -
Mary Leonard
Arline and Pete Harman Professor and Professor of Medicine (Nephrology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsMy multidisciplinary research program is focused on (1) the detrimental effects of glucocorticoids, sarcopenia and inflammation on bone development in pediatric diseases, (2) the long-term effects of childhood cancer on bone and muscle quality, (3) the assessment of renal osteodystrophy using novel micro-imaging techniques, (4) the effects of vitamin D deficiency on physical function and cardiovascular disease, and (5) the evaluation of biomechanical interventions as anabolic bone therapies.
-
John Leppert
Professor of Urology and, by courtesy, of Nephrology
On Leave from 06/02/2024 To 08/24/2024Current Research and Scholarly InterestsOur research aims to improve the global quality of care for patients with Urologic Cancer with a particular focus on kidney cancer. We are investigating novel proteomic platforms and assays to diagnose kidney cancer and predict response to therapy. We are evaluating the comparative effectiveness of various kidney cancer surgeries and their impact on chronic kidney disease and its downstream effects. We are applying epidemiology, bioinformatics, and health services methods to urologic conditions.
-
Lawrence Leung
Maureen Lyles D'Ambrogio Professor in the School of Medicine
Current Research and Scholarly InterestsOur long term interest is to have a better understanding of the natural antithrombotic pathways and the pathophysiology of vascular thrombosis. We have focused on thrombin, the key enzyme in the blood clotting cascade.Our goal is to develop new antithrombotic agents and devise new diagnostic tests for vascular thrombotic disorders.
-
Eleanor Levin
Clinical Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsCardiovascular Value Based Care, Cardio-Obstetrics, Dyslipidemia Treatment
-
Deborah J Levine, MD, FCCP, FAST
Clinical Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine
BioDr. Deborah Jo Levine is a board-certified pulmonologist and lung transplantation and pulmonary hypertension specialist. She is a clinical professor of medicine in the Department of Pulmonary, Allergy, and Critical Care Medicine. Dr. Levine also serves as director of lung transplant outreach for Stanford Health Care.
Dr. Levine is internationally recognized for her work in lung transplantation and pulmonary hypertension (PH). She has been instrumental in developing international guidelines for defining, diagnosing, and managing antibody-mediated rejection (AMR) after lung transplantation. She has served as chair of pulmonary AMR guidelines for the International Society of Heart and Lung Transplantation.
Dr. Levine’s research interests include lung allograft monitoring and risk assessment. Her research has also included monitoring lung allograft health using donor-derived cell-free DNA (dd-cfDNA)—a technique pioneered at Stanford Medicine. She has received National Institutes of Health (NIH) funding as a clinical investigator. Dr. Levine is a co-chair of the ALAMO (AlloSure Lung Assessment and Metagenomics Outcomes) Study national registry. She has been involved in many clinical trials in lung transplantation and pulmonary hypertension.
As a respected educator and researcher, Dr. Levine has led and contributed to dozens of abstracts, presentations, and peer-reviewed articles. She has also written several books and book chapters on pulmonary hypertension, interstitial lung disease, pulmonary vascular disorders, and lung transplantation.
Dr. Levine is editor-in-chief for Advances in Pulmonary Hypertension, the quarterly journal of the Pulmonary Hypertension Association. She is an editorial board member of The Journal of Heart and Lung Transplantation and an ad hoc reviewer for several other industry journals. Dr. Levine also serves as a grant reviewer and section study reviewer for the American College of Chest Physicians and the American Society of Transplantation.
Dr . Levine is a fellow of the American College of Chest Physicians and the American Society of Transplantation. She is also the chair of the Diffuse Lung Disease and Lung Transplant Network and the incoming vice chair of the Council of Networks for the American College of Chest Physicians (CHEST). -
Joseph Levitt, MD, MS
Associate Professor of Medicine (Pulmonary and Critical Care Medicine)
Current Research and Scholarly InterestsMy research focuses on the physiolgogic and biomarker characteristics of early acute lung injury (ALI) prior to need for mechanical ventilation. While, to date no pharmacologic treatment has improved survival in ALI, following the paradigm of early goal directed therapy for severe sepsis, clinical benefit may derive from identifying patients and initiating treatment prior to the need for positive pressure ventilation (and therefore prior to meeting current study entry criteria).
-
Lee Levitt
Professor of Medicine (Hematology) at the Santa Clara Valley Medical Center, Emeritus
Current Research and Scholarly InterestsLow molecular-weight heparins Clinical trials with anti-thrombotics Clinical trials in patients with leukemia, breast cancer and myeloma Medical education.
-
Ronald Levy, MD
Robert K. and Helen K. Summy Professor in the School of Medicine
On Partial Leave from 05/16/2024 To 05/15/2025Current Research and Scholarly InterestsClinical Interests: lymphoma. Research Interests: Immunology and molecular biology of lymphoid malignancy; molecular vaccines for cancer.
-
Eldrin F. Lewis, MD, MPH
Simon H. Stertzer, MD, Professor
BioDr. Lewis is a board-certified, fellowship-trained specialist in cardiovascular medicine. He is the chief of the Division of Cardiovascular Medicine and a professor of cardiovascular medicine.
Dr. Lewis is an esteemed clinician-scientist who specializes in the care of patients with advanced heart failure. He is an internationally recognized expert on heart failure, heart transplant, and quality of life for heart failure patients. He cares deeply about his patients as well as his colleagues, the hospital, and the School of Medicine. Dr. Lewis is committed to diversity and inclusion, as well as expanding Stanford clinical research initiatives.
A fundamental principle of Dr. Lewis’ practice is his belief that “there is more to life than death,” that cardiovascular care should go beyond helping patients survive to also helping them enjoy the best possible quality of life.
Dr. Lewis has deep expertise in conducting clinical trials examining diagnostic and therapeutic approaches to heart failure. He has done innovative work to create systems for incorporating quality of life measures for cardiovascular patients into electronic health records. This research has received support from the National Heart, Lung and Blood Institute and the National Institutes of Health.
Much of his quality of life research has focused on patient-reported outcomes. Dr. Lewis emphasizes the importance of looking at how a disease, whether chronic or acute, impacts people’s ability to function and perform their activities of daily living. Strategies to improve patients’ well-being focus not only on their physical symptoms but also on depression, anxiety, exercise capacity, and ability to function in daily living.
Dr. Lewis’ commitment to expanding clinical research initiatives will give patients more opportunities to participate in the clinical trials and access the latest care strategies that can translate into better outcomes. The goal is early access to the most advanced technology, pharmacology, and device therapy that can change outcomes for the better. He also envisions forming closer partnerships with community cardiologists and capitalizing further on Stanford’s proximity to and unique relationships with the digital technology leaders of Silicon Valley to enhance the use of digital technology for monitoring patients, optimizing treatment, and tracking outcomes.
He has authored nearly 200 articles published in peer-reviewed journals including the New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, JAMA Cardiology, JAMA Internal Medicine, and many more. He is also on multiple editorial boards for cardiovascular journals and was an associate editor for Circulation–Heart Failure. In addition, he is an author of professional society clinical practice guidelines and scientific statements from both the American Heart Association (AHA) and the Food and Drug Administration.
Dr. Lewis’ honors for clinical care, scholarship, and research include the Joel Gordon Miller Award for community service and leadership from the University of Pennsylvania School of Medicine. He also was one of the first recipients of the Minority Faculty Development Award, which recognizes the research potential of young physicians. Dr. Lewis has received a grant from the Robert Wood Johnson Foundation to study the role of quality of life assessment in clinical decision making in patients with heart failure.
He is a fellow of the American College of Cardiology and the National American Heart Association (AHA) Research Committee. In addition, Dr. Lewis was as a member of the AHA Founders Affiliate Board of Directors, chair of the Council on Clinical Cardiology, and research chair of the Association of Black Cardiologists. He also serves on scientific committees to review grants for the AHA and on the FDA Task Force for the Standardization of Definitions for Endpoint Events in Cardiovascular Trials. -
Daniel Yuhang Li
Instructor, Medicine - Cardiovascular Medicine
BioI am a physician scientist in the Division of Cardiology at Stanford. My clinical interest is at the intersection of inflammation, autoimmunity and cardiovascular disease in a field called 'Cardio-Rheumatology'. Patients with rheumatologic diseases typically have an elevated cardiovascular disease risk profile along with an insidious onset. Moreover, with the ever-expanding biologic drug formulary for patients, it is important for us to characterize the cardiovascular effects of these medications. In my research, I believe that understanding how inflammatory and autoimmune mechanisms modify coronary artery disease can help us develop a novel perspective towards treating atherosclerosis beyond lipid lowering. My research goal is to advance novel therapeutics for atherosclerosis by leveraging my expertise in genetics, computational biology, and experience with diverse model organism perturbation models. My strategy employs a ‘systems’ approach, starting with human population variations at the genetic level and integrating findings across RNA, protein, and model organism studies. This comprehensive synthesis aims to grasp the overarching biological narrative, thereby facilitating the development of translational therapies that transform concepts from bench to bedside.
-
Ron Li
Clinical Associate Professor, Medicine
BioRon Li is a Clinical Associate Professor of Medicine in the Division of Hospital Medicine and Center for Biomedical Informatics Research at Stanford University School of Medicine. As the Medical Informatics Director for Digital Health at Stanford Health Care, he provides medical and informatics direction for the health system's enterprise digital health portfolio, including expanding digital referral networks and virtual care modalities. He is the co-founder and Director for the Stanford Emerging Applications Lab (SEAL), which helps clinicians and staff build ideas into novel digital products that are prototyped and tested for care delivery at Stanford Health Care.
Ron's academic interests focus on the "delivery science" of new technological capabilities such as digital and artificial intelligence in healthcare and how to design, implement, and evaluate new tech enabled models of care delivery. Ron's work spans across multiple disciplines, including clinical medicine, data science, digital health, information technology, design thinking, process improvement, and implementation science. He has consulted for various companies in the digital health and artificial intelligence space. He is an attending physician on the inpatient medicine teaching service at Stanford Hospital and is the Associate Program Director for the Stanford Clinical Informatics Fellowship. -
David Liang, MD, PhD
Professor of Medicine (Cardiovascular) at the Stanford University Medical Center, Emeritus
BioStanford researchers are creating a micro-device that physicians could guide through the body to help diagnose and treat clogged arteries and other diseases. Tethered to the outside world by a thin wire, a tiny machine creeps through blood vessels, searching out deadly plaques and obliterating them with a zap of a laser. While a laser will come later, for now David Liang, MD, PhD, is focusing on a tiny eye that could give physicians an unprecedented view into blood vessels.
-
Charles Liao
Clinical Assistant Professor, Medicine
Current Research and Scholarly InterestsEducational Curriculum: Working with Professional Interpreters
-
Ronglih Liao
Douglass M. and Nola Leishman Professor of Cardiovascular Disease
BioDr. Liao is a Professor of Medicine and co-Director of Stanford Cardiac Amyloid Center. The major goal of her research program focuses on understanding the mechanisms that underlie the pathophysiology of heart failure and developing novel treatments to combat this process. Her laboratory has played an international leading role in the study of amyloid light chain (AL) cardiomyopathy, a rare and fatal form of cardiovascular disease. We have described the underlying pathophysiologic basis for amyloid cardiomyopathy and found that the circulating amyloidogenic light chain proteins that characterize this disease directly result in a specific cardiotoxic response. Consequently, our research work has redefined AL cardiomyopathy and has raised new treatment approaches. More recently, her research efforts have expanded to include transthyretin (ATTR) cardiac amyloidosis.
In line with her goal of revealing novel therapeutic strategies for patients with cardiovascular disease, our efforts have also focused on characterizing and harnessing endogenous cardiac regenerative mechanisms. Her laboratory initially demonstrated the therapeutic potential of exogenous primitive muscle cells delivered to the injured heart. This work was among the earliest milestones in the field and served as the basis for an international trial of cell-based therapy. Subsequently, Liao lab identified and characterized a population of cardiac progenitor cells and its relationship and dynamic activity following cardiac injury in the adult heart. Her laboratory aims to reveal the molecular mechanisms regulating the endogenous regenerative capacity of the heart and to harness such repair mechanisms for the treatment of cardiovascular disease. Dr. Liao has lectured extensively on both amyloid cardiomyopathy and stem cell biology, and have maintained a history of independent NIH funding in these areas for more than two decades.
Over the course of her academic career, she has taken the greatest pride in mentoring the next generation of scientists. Dr. Liao has had the privilege to supervise several dozen students, postdoctoral fellows, and junior faculty, many of whom have gone on to independent academic careers at the highest institutions. Her contribution to the advancement of scientific knowledge also includes lecturing at various university and academic institutions as well as at scores of conferences and symposia locally, nationally, and internationally. -
Michaela Liedtke
Associate Professor of Medicine (Hematology)
Current Research and Scholarly Interests1) Design of phase I/II trials for the treatment of Multiple Myeloma and Amyloidosis
2) Conduct of clinical trials to improve the treatment of patients with acute lymphoblastic leukemia (ALL)
3) Outcomes research using clinical databases for patients with Multiple Myeloma and Amyloidosis -
Michael Lim, M.D.
Professor of Neurosurgery and, by courtesy, of Radiation Oncology (Radiation Therapy), of Medicine (Oncology), of Otolaryngology - Head & Neck Surgery (OHNS) and of Neurology
BioDr. Lim is the Chair of the Department of Neurosurgery and a board-certified neurosurgeon specializing in brain tumors and trigeminal neuralgia.
Dr. Lim’s clinical interests include the treatment of benign and malignant brain tumors, with special interest in gliomas, meningiomas, metastatic tumors, and skull base tumors. Dr. Lim also specializes in surgical treatments for trigeminal neuralgia. During his time at Johns Hopkins, Dr. Lim built one of the largest brain tumor and trigeminal neuralgia practices and utilized the most advanced surgical technologies and techniques for his patients. As a passionate voice for patient experience, he has been recognized by his peers and patients for his integrity and compassionate care, including a Service Excellence Award from HealthNetwork Foundation.
As a mentor, he has garnered numerous teaching awards, including being honored as an outstanding teacher by Johns Hopkins University School of Medicine. He is actively involved in shaping education for neurosurgery and oncology across the United States and around the world. He is the recipient of the prestigious 2023 Abhijit Guha Award in Neuro-Oncology.
Dr. Lim’s research interests focus on harnessing the immune system to fight cancer. His laboratory focuses on understanding mechanisms of immune evasion by cancer cells. He has successfully translated his findings from the laboratory to the clinics and has conducted and led several large national immunotherapy clinical trials for brain tumors.
Dr. Lim’s bibliography contains well over 300 articles on topics such as immunotherapy for glioblastoma, long-term survival of glioma patients treated with stereotactic radiation, and treatment of neuropathic pain. His work has appeared in Science Translational Medicine, Clinical Cancer Research, Lancet Oncology, Nature Immunology, and many more publications. He also has written 20 book chapters and monographs.
Dr. Lim is a world leader in immunotherapy for brain tumors. In addition to being invited world-wide to give lectures and seminars, he has given platform presentations on the topics of immunotherapy for brain tumors, neurosurgical techniques and management of brain tumors at the American Society of Clinical Oncologists, American Academy of Neurological Surgeons, Radiological Society of North America, Annual Symposium on Brain and Spine Metastases, Congress of Neurological Surgeons, and other meetings. In addition, he has served as platform chairman of the CNS session at the American Society for Clinical Oncology conference.
Dr. Lim is a member of the American Society for Clinical Oncology, Congress of Neurological Surgeons, American Association of Neurological Surgeons, and Society for Neuro-Oncology. Dr. Lim served as the program co-chair of the Society for Neuro-Oncology and CNS section of the American Society for Clinical Oncology. He also served on many executive committees, including the Executive Committee for the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons. -
David Limsui
Clinical Professor, Medicine - Gastroenterology & Hepatology
BioThroughout my career I have been extensively involved in post-graduate medical education and training of residents and fellows. I served on the AGA Future Trends Committee tasked with reporting the future of gastroenterology training programs and have been admitted into the AGA Academy of Educators. I joined Stanford for the incredible opportunity to be part of a dynamic division with excellent and dedicated faculty where one can achieve their greatest potential. I share the honor and privilege of leading our fellowship program and in the joy of teaching such talented and inspiring fellows. Together we strive to provide the best educational experience for our fellows to become outstanding gastroenterologists and future leaders in academic medicine.
My subspecialty areas of focus are inflammatory bowel disease and general gastroenterology. -
Bryant Lin
Clinical Professor, Medicine - Primary Care and Population Health
Current Research and Scholarly Interests-Digital Health
-Medical device design, prototyping, testing and clinical trials
-Behavioral determinants of chronic disease
-Novel diagnostic processes for medical mysteries
-Asian Health
-Medical Humanities and Arts
-Medical Technology -
Janice Lin
Clinical Assistant Professor, Medicine - Immunology & Rheumatology
BioDr. Lin specializes in the diagnosis and treatment of rheumatologic conditions such as rheumatoid arthritis, lupus, myositis, gout, and seronegative spondyloarthropathies. She received additional training in autoimmune skin diseases and has a special clinical and research interest for psoriasis/psoriatic arthritis, dermatomyositis, cutaneous lupus/systemic lupus. She leads a combined rheumatology-dermatology clinic with Dr. Matthew Lewis in the dermatology department to take care patients collaboratively. Dr. Lin is a graduate of USSONAR (Ultrasound School of North American Rheumatologists) program and performs diagnostic musculoskeletal ultrasound evaluation and interventions. In addition to her clinical work, she leads the quality improvement effort for the division and her most recent projects are focused on patient-reported outcome in rheumatoid arthritis and vaccinations for patients in the rheumatology clinic.
-
Steven Lin
Clinical Professor, Medicine - Primary Care and Population Health
Current Research and Scholarly InterestsArtificial intelligence and machine learning in healthcare
Primary care and population health
Value added medical education -
Brian Linde, MD
Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioDr. Linde is a double board-certified, fellowship-trained internal medicine doctor with the Department of Medicine, Division of Primary Care & Population Health at Stanford University School of Medicine. He is board certified in both internal medicine and occupational and environmental medicine. He is fellowship trained in occupational and environmental medicine.
Dr. Linde specializes in preventing, managing, and treating work-related injuries and diseases. He uses his expertise to improve the physical and mental wellness of his patients while reducing their exposure to occupational and environmental hazards. As a public health expert, Dr. Linde also focuses on enhancing the health of entire populations through strategies and policies that benefit communities as a whole.
His academic interests include inhalational exposures and occupational lung diseases. During the COVID-19 pandemic, Dr. Linde studied how to increase adherence to infection prevention recommendations in clinical settings. He has also worked on guidance related to exposure to per- and polyfluoroalkyl substances (PFAS). These chemicals, which are found in water, food, and fabrics, are an ongoing public health concern. Dr. Linde has also researched how to improve the mental and physical health of medical students and ways to prevent physician burnout.
Dr. Linde has published in many peer-reviewed journals, including Current Opinion in Pulmonary Medicine and Academic Medicine. As a member of the Committee on the Guidance on PFAS Testing and Health Outcomes, Dr. Linde contributed to Guidance on PFAS Exposure, Testing, and Clinical Follow-Up, a publication of the National Academies of Sciences, Engineering, and Medicine. He was also a reviewer for Archives of Environmental & Occupational Health and the American Journal of Industrial Medicine.
He has written book chapters for Modern Occupational Diseases: Diagnosis, Epidemiology, Management and Prevention and Patty’s Industrial Hygiene. He wrote about preventing occupational and environmental pulmonary disorders for the Merck Manuals Professional Edition. Dr. Linde has been invited to speak at workshops and presentations all over the nation about a range of topics, including environmental health risks in underserved communities and the health effects of floods.
Dr. Linde is a member of the American Board of Internal Medicine and the American Board of Preventive Medicine. He is also a member of the American College of Physicians and the American College of Occupational and Environmental Medicine. -
Malene Lindholm
Instructor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsInterested in the genetics of human performance and the multi-omic response to exercise and training for optimizing human health.
-
Evelyn Bin Ling
Clinical Assistant Professor, Medicine
Current Research and Scholarly InterestsMy current research interests are in clinical trials related to COVID19 and hospitalized patients.
-
Eleni Linos, MD, MPH, DrPH
Associate Dean for Research, Ben Davenport and Lucy Zhang Professor of Medicine, Professor, of Medicine (Center for Digital Health) and, by courtesy, of Epidemiology and Population Health
BioEleni Linos MD, MPH, DrPH, is the Director of the Stanford Center for Digital Health. She is a Professor of Dermatology and Epidemiology at Stanford University. Dr. Linos also serves as an Associate Dean for Research, leading the KL2 Research Training Program.
Dr. Linos' research focuses on the use of technology in health, dermatology, public health, cancer prevention and the care of older adults. She is dually trained in epidemiology and dermatology and is the principal investigator of several NIH funded studies aimed at improving the lives of patients. She received her medical degree from Cambridge and Oxford universities in the UK, received a masters and doctoral degree from the Harvard School of Public Health and completed her residency at Stanford. -
Anne Liu
Clinical Associate Professor, Pediatrics - Immunology and Allergy
Clinical Associate Professor (By courtesy), Medicine - Pulmonary, Allergy & Critical Care MedicineBioDr. Liu is a board-certified, fellowship-trained specialist in allergy/immunology and infectious disease. She is also a clinical associate professor in the Department of Medicine, Division of Infectious Diseases and the Department of Pediatrics, Division of Allergy, Immunology, and Rheumatology at Stanford University School of Medicine.
Dr. Liu treats infections in patients with compromised immune systems, whether due to a primary immune deficiency or a condition like cancer or organ transplant. She helps patients to develop tolerance to medications they are allergic to so that they can receive the best, and sometimes the only, treatments available to them. She also treats allergies to antibiotics, aspirin, NSAIDs, chemotherapy, and more. She sees patients both long term and for urgent referrals, such as in cases of perioperative anaphylaxis. Dr. Liu also helps pediatric patients manage drug and food allergies.
One of Dr. Liu’s areas of focus is helping patients with allergies to antibiotics determine when they have lost an allergy, what antibiotics they can tolerate, and when to induce tolerance to an antibiotic. This not only can benefit the patient, but also have a positive public health impact, as labeling patients with a penicillin allergy may negatively affect their care and increase use
of broad-spectrum antibiotics.
She collaborates closely with colleagues from other disciplines, including pulmonology, otolaryngology, oncology, cardiology, dermatology, anesthesiology, and surgery. Her key objective in working with referring physicians is to help them safely deliver the best care for their patients.
For patients and families, Dr. Liu strives to help them navigate their care journey with as much ease and dignity as possible during what may be the most challenging time of their life. Her goal is to offer patients options, even when it may appear that they have no options left.
Dr. Liu’s research interests include optimizing care of patients with antibiotic allergies, including through use of decision support tools.
Dr. Liu has authored articles in the New England Journal of Medicine, Journal of Immunology, Journal of Allergy and Clinical Immunology in Practice, Clinical and Experimental Allergy, Mucosal Immunology, Diagnostic Microbiology and Infectious Disease, Science, and other publications. Dr. Liu authored the book chapter “Hypersensitivity Reactions to Monoclonal Antibodies” in Drug Allergy Testing.
Dr. Liu is certified in infectious disease by the American Board of Internal Medicine and in allergy and immunology by the American Board of Allergy and Immunology. She is also a member of the American College of Physicians, Infectious Diseases Society of America, and American Academy of Allergy, Asthma, and Immunology.
She has given presentations on antibiotic allergies, drug desensitization, and aspirin-exacerbated respiratory disease, among other topics. Dr. Liu’s honors include recognition from the American Academy of Asthma, Allergy, and Immunology, the American Medical Women’s Association, and the National Institutes of Health. -
Christine Kee Liu
Assistant Professor of Medicine (Primary Care and Population Health)
BioDr. Liu and her research program are dedicated to improving the lives of older adults with kidney disease. Currently her research focuses on mobility, which is the ability to move safely and reliably from one place to another. In older adults, poor mobility strongly predicts future disability and death. Retaining mobility has been cited by older adults as fundamental to quality to life; yet many older persons with kidney disease, especially those with late stage chronic kidney disease or outright kidney failure, have trouble just walking across the room or transferring to a chair. Dually trained in geriatric medicine and epidemiology, Dr. Liu also has significant expertise in older adult clinical trials, including safety trials of novel agents as well as intervention studies to reduce infections in older populations.
-
Nathan Lo
Assistant Professor of Medicine (Infectious Diseases)
Current Research and Scholarly InterestsOur research laboratory is interested in studying the transmission of infectious diseases and impact of public health interventions with an ultimate goal of informing public health policy. We study a diverse set of pathogens, both domestically and internationally, including vaccine-preventable infections (including COVID-19) and neglected parasitic diseases (such as schistosomiasis). Our group applies diverse computational methodologies, including tools from fields of epidemiology, mathematical and statistical modeling, simulation, and policy analysis.
A large emphasis of our work is translating scientific evidence into public health policy. Our track record includes multiple studies that have changed policy in the fields of neglected parasitic diseases and COVID-19. We work closely with policy organizations like the World Health Organization and the California Department of Public Health. Nathan served as the lead writer of the World Health Organization guidelines on schistosomiasis (2022) and strongyloidiasis (2024).
Our current research focuses on the following areas:
(1) Vaccine-preventable infectious diseases (including COVID-19) in the United States, with a focus on studying vaccines and transmission dynamics
(2) Public health strategies for control and elimination of globally important neglected infectious diseases, such as helminths infections (schistosomiasis, strongyloidiasis) and typhoid fever
Hiring
We are seeking to fill multiple research positions at all levels. Candidates interested in working on computational public health research related to infectious diseases with a strong quantitative background are highly encouraged to apply. If you an interested, please submit a cover letter, CV, and names of two references to Nathan.Lo@stanford.edu. -
Karl Lorenz
Professor of Medicine (Primary Care and Population Health)
BioDr. Karl Lorenz, MD MSHS is a general internal medicine and palliative care physician, and Section chief of the VA Palo Alto-Stanford Palliative Care Program. Formerly at the VA Greater Los Angeles, Dr. Lorenz directed palliative care research at the VA Center for Innovation to Implementation and served on the faculty at the UCLA School of Medicine. Dr. Lorenz is a member of the VA’s national Hospice and Palliative Care Program (HPC) leadership team, director of the operational palliative care Quality Improvement Resource Center (QuIRC), and adjunct facility staff member at RAND. Dr. Lorenz’s work and leadership has been influential to the field of palliative care research. Under Dr. Lorenz’s leadership, since 2009 the Quality Improvement Resource Center (QuIRC) has served as one of three national leadership Centers responsible for strategic and operational support of the VA’s national hospice and palliative care programs. QuIRC develops and implements provider facing electronic tools for the VA’s national electronic medical record to improve the quality of palliative care. In that role, Dr. Lorenz participates with the national leadership team in strategic planning, policy development, and providing resources to support operational efforts. Dr. Lorenz has contributed to the field of global palliative care, serving the World Health Organization in its development of Palliative Care for Older People and leading methods for Palliative Care Essential Medications.
-
Kate Lorig
Professor (Research) of Medicine (Immunology and Rheumatology), Emerita
Current Research and Scholarly InterestsCommunity based psycoeducational intervention studies of disease self management for people with chronic diseases. arthritis, lung diseases, heart disease AIDs, low back pain and diabetes. Programs and studies in Spanish and English. Interventions are in small groups, mailed or on the Internet.
-
Anson Lowe
Associate Professor of Medicine (Gastroenterology and Hepatology), Emeritus
Current Research and Scholarly InterestsThe laboratory is focused on the relationship between injury, wound healing, and cancer. Esophageal, gastric, and pancreatic cancers are a focus. We are particularly interested in the regulation of cell signaling by EGFR, the EGF receptor. In addition to cancer pathogenesis, active projects include the development of new diagnostic assays and drugs.
-
Henry J. Lowe, MD
Associate Professor of Medicine (General Medical Disciplines) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsMy research in the field of biomedical informatics over the past 30 years has focused on the development of novel uses of information technology and computer science to improve human health. My current interests include the Electronic Health Record (EHR), biomedical knowledge representation, Internet applications in healthcare, clinical data warehouses, clinical data and text mining, academic social networking and the use of information technology to support clinical and translational research.
-
Robert Lowsky
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsDr. Lowsky's research is focused on understanding the role of regulatory T cells in the prevention of GVHD and in promoting immune tolerance following organ transplantation.
-
Sydney X. Lu
Assistant Professor of Medicine (Hematology)
BioSydney Lu is a hematologist and medical oncologist in the Division of Hematology, Department of Medicine, studying novel therapeutics for challenging cancers and immune disorders.
Sydney's research career started with graduate studies in the laboratory of Dr. Marcel van den Brink at Memorial Sloan Kettering Cancer Center (MSKCC) studying the biology of pathologic donor T cells during graft-versus-host-disease and beneficial T cells mediating graft-versus-tumor effects after allogeneic bone marrow transplant, as well as the role of the thymus in regenerating healthy and protective donor-derived T cells post-transplant.
The direct relevance of these cellular therapies and their immediate translational applicability to patients inspired him to attend medical school at Stanford and further training in hematology and medical oncology at Memorial Sloan Kettering. There, as a fellow and junior faculty member, he studied disordered RNA splicing in cancer in the laboratory of Dr. Omar Abdel-Wahab, with the goal of developing novel drugs targeting RNA splicing. This work has led to observations that targeted degradation of the RNA binding protein RBM39 may be a feasible therapeutic for the treatment of myeloid cancers bearing RNA splicing factor mutations and that pharmacologic RNA splicing inhibition can generate MHC I-presented peptide neoantigens which are exploitable for immunotherapy in model systems.
Sydney's laboratory is broadly interested in studying RNA processing and splicing in the contexts of:
1) normal and pathologic immunity and immunotherapy
2) cancer biology
3) normal and malignant hematopoiesis -
Stephen Luby
Lucy Becker Professor of Medicine, Senior Fellow at the Woods Institute for the Environment, Freeman Spogli Institute for International Studies and Professor, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsDr. Luby’s research interests include identifying and interrupting pathways of infectious disease transmission in low income countries.
-
George Lui
Clinical Professor, Medicine - Cardiovascular Medicine
Clinical Professor, Pediatrics - CardiologyCurrent Research and Scholarly InterestsAdult Congenital Heart Disease
-
Mitchell R. Lunn
Associate Professor of Medicine (Nephrology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsLGBTQIA+ health
-
Kevin M Lutley
Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioDr. Lutley is a primary care doctor. He is board certified in internal medicine.
For every patient, he creates a customized care plan. Plans focus on helping each person enjoy the best possible health and wellness.
Dr. Lutley has helped advance care through research. He has shared his research discoveries with his peers in invited presentations. Topics include drug prices in community pharmacies and the quality of interactions between patients and resident physicians.
While an internal medicine resident at Stanford, Dr. Lutley served as a member of the Stanford Ambulatory Care Excellence Program. This initiative aims to enhance the quality of outpatient primary care.
Dr. Lutley helps educate the primary care doctors of tomorrow. He is a clinical assistant professor of primary care and population health in the Stanford Department of Medicine, Division of Primary Care.
Before joining Stanford, Dr. Lutley performed needs assessments and care coordination with local public health agencies in Flint, Michigan.
Recognition for his achievements includes induction in the Gold Humanism Honor Society. This national organization honors senior medical students, residents, teachers and others for excellence in clinical care, leadership, and compassion. Additional honors for Dr. Lutley include induction in Alpha Omega Alpha, the honor society in the field of medicine.
From Stanford University, he received the Julian Wolfsohn Award. This honor goes to residents who demonstrate exemplary professionalism, teaching, and dedication to patient care.
Dr. Lutley is a member of the American College of Physicians. -
Crystal Mackall
Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine
Current Research and Scholarly InterestsRecent clinical studies, by us and others, have demonstrated that genetically engineered T cells can eradicate cancers resistant to all other therapies. We are identifying new targets for these therapeutics, exploring pathways of resistance to current cell therapies and creating next generation platforms to overcome therapeutic resistance. We have discovered novel insights into the biology of human T cell exhaustion and developed approaches to prevent and reverse this phenomenon.
-
David Magnus, Ph.D.
Thomas A. Raffin Professor of Medicine and Biomedical Ethics and Professor (Teaching) of Medicine (Primary Care and Population Health)
Current Research and Scholarly InterestsGenetic testing, gene therapy, genetically engineered organisms, and the history of eugenics. Stem cell research and cloning, and egg procurement. Examining ethical issues in reproductive technologies. Organ transplantation including donation after cardiac death, ethics of listing decisions. End of life issues in both adults and children.
-
Kenneth Mahaffey
Professor of Medicine (Cardiovascular Medicine)
BioClinical Focus: Cardiovascular Medicine: Atrial Fibrillation; Chronic CAD; ACS;
Research Focus:
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Associate Dean, Clinical Research School of Medicine; Vice Chair of Clinical Research Department of Medicine; Director Stanford Center for Clinical Research; Member of the Stanford IRB
Professional Training:
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Faculty Cardiovascular Medicine -
Anurag Mairal
Adjunct Professor, Medicine - Cardiovascular Medicine
BioDr. Anurag Mairal is an Adjunct Professor of Medicine and the Director, Global Outreach Programs at Stanford Byers Center for Biodesign, Stanford University. He is also a Faculty Fellow and Lead for Technology Innovation and Impact at Center for Innovation in Global Health. In these roles, he leads initiatives focused on applying the biodesign process to resource-constrained se ttings globally. Further, he facilitates opportunities for students, faculty and fellows at Stanford to work on global healthcare needs. He is founding co-Director for MED 232, Global Health: Scaling Health Technology Innovations in Low Resource Settings, and was part of the founding faculty team for BIOE 371, Global Biodesign: Medical Technology in an International Context, graduate-level courses offered to engineering, business, and medical students at Stanford University. Earlier, he served as Associate Director for the Stanford-India Biodesign and Singapore-Stanford Biodesign programs. He serves as the Founding Chair of BME IDEA APAC, a community of medtech innovation programs in Asia Pacific, partnering closely with the industry and academia in the region. He is also an Honorary Professor at University of Cape Town, South Africa. Concurrently, he is a co-founder and Executive Vice President of Orbees Medical, a SF Bay Area-based strategy consulting firm serving global healthcare industry, with a focus on medtech, pharmaceutical, and digital health industry.
Dr. Mairal has an extensive background in medical technology development and commercialization, collaborating with partners in the U.S., India, China, and other emerging markets to advance product development, manufacturing, and distribution. Recently, he took a sabbatical for two years to take a senior leadership role at PATH, a major global health nonprofit based in Seattle. In this role, he oversaw research and development, commercialization, and implementation of technologies in PATH’s medical devices, diagnostics, and digital health divisions. Previously, he held several positions at Johnson & Johnson, including Business Development Director and Product Director for structural heart, cardiology, and peripheral vascular products at Cordis. Before joining J&J, he was a Group Leader and a Process Development Manager at Membrane Technology and Research (MTR). At MTR, he was responsible for business development, strategic alliances, and product development in the bioseparations area. An active mentor to entrepreneurs and industry professionals, he serves as the chair of PATH’s Bay Area Leadership Council; chair of the board at EPPIC Global Network; chair of Faculty Alumni Network at IIT Bombay Heritage Foundation; and President of Sewa International - Bay Area.
Dr. Mairal earned a PhD in chemical engineering from the University of Colorado at Boulder and an MBA from the Haas School of Business at the University of California at Berkeley. He also holds an MS in chemical engineering from the Indian Institution of Technology in Mumbai and a BS in chemical engineering from National Institute of Technology, Raipur. Dr. Mairal was a post-doctoral fellow at the University of Twente, Netherlands and at University of Michigan, Ann Arbor. At BerkeleyHaas, he was a founding co-Chairman of the South Asia Business Conference and Chair of the Biotech Panel for the Asia Business Conference. His work has been published in more than 30 publications, and he has seven issued patents. -
Amrapali Maitra
Clinical Assistant Professor, Medicine
BioAmrapali Maitra is a clinician, educator, and scholar with training from Harvard and Stanford as well as a Paul and Daisy Soros Fellow for New Americans (2013). Her clinical practice emphasizes humanism and attention to health equity through structural competency. As an educator, she is committed to diversity and inclusion in the learning environment for pre-medical, medical, and graduate medical trainees, as well as centering patients as teachers. Her scholarship focuses on intimate partner violence, trauma-informed care, medical education, and the humanities.
-
Ravi Majeti MD, PhD
Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Virginia and D. K. Ludwig Professor and Professor of Medicine (Hematology)
Current Research and Scholarly InterestsThe Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for human hematopoietic cells.
-
Joshua Makower
Yock Family Professor and Professor of Bioengineering
Current Research and Scholarly InterestsDr. Josh Makower is the Boston Scientific Applied Bioengineering Professor of Medicine and of Bioengineering at the Stanford University Schools of Medicine and Engineering and the Director of the Stanford Byers Center for Biodesign, the program he co-founded with Dr. Paul Yock twenty years ago. Josh helped create the fundamental structure of the Center’s core curriculum and is the chief architect of what is now called “The Biodesign Process.” Over the past 20 years since Josh and Paul founded Biodesign, this curriculum and the associated textbook has been used at Stanford and across the world to train hundreds of thousands of students, faculty and industry leaders on the Biodesign process towards the advancement of medical innovation for the improvement of patient care. Josh has practiced these same techniques directly as the Founder & Executive Chairman of ExploraMed, a medical device incubator, creating 9 companies since 1995. Transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard & TransVascular, acquired by Medtronic. Other ExploraMed/NEA ventures include Moximed, NC8 and Willow. Josh is also a Special Partner at NEA where he supports the healthcare team and medtech/healthtech investing practice. Josh serves on the boards of Allay Therapeutics, Revelle Aesthetics, Setpoint Medical, DOTS Technologies, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow and Coravin. Josh holds over 300 patents and patent applications. He received an MBA from Columbia University, an MD from the NYU School of Medicine, a bachelor’s degree in Mechanical Engineering from MIT. Josh is a Member of the National Academy of Engineering and the College of Fellows of The American Institute for Medical and Biological Engineering and was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018.
-
Jose R. Maldonado, MD, FACLP, FACFE
John and Terry Levin Family Professor of Medicine and Professor, by courtesy, of Emergency Medicine and of Medicine
Current Research and Scholarly InterestsPathophysiology and Management of Delirium, Acute Brain Failure and Cognitive Impairment, Neuropsychiatric Sequelae of Traumatic Brain Injury, Factitious Disorder & Munchausen's Syndrome, Cultural Diversity in Medical Care, Psychiatric Complications of Bone Marrow Transplantation, Conversion Disorder, Depression in the Medically Ill, Neuropsychiatric Sequelae of Chronic Fatigue Syndrome.
-
Gabriel Mannis
Associate Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research focuses on the development of more effective, less toxic therapies for patients with AML and other high-risk hematologic malignancies. We study biologic correlates that predict response to therapy as well as factors/interventions that improve quality-of-life for patients struggling with blood-borne cancers.
-
Arek Melkon Manugian, MD
Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioDr. Manugian is a board-certified internal medicine doctor at Stanford Primary Care in Portola Valley. He is also a clinical assistant professor in the Division of Primary Care and Population Health in the Department of Medicine at Stanford University School of Medicine.
He has experience diagnosing, managing, and treating a wide range of conditions. These include gastrointestinal disorders, hypertension (high blood pressure), and obesity. Dr. Manugian develops an individualized care plan for each one of his patients.
Dr. Manugian’s research interests include blood pressure medication, gastric bypass surgery, and restless legs syndrome. He received a student research grant to study how the body processes glucagon (a hormone that regulates blood sugar) following gastric bypass surgery. Dr. Manugian has also studied muscle inflammation as a rare side effect of statins (drugs that lower cholesterol). He monitored a clinical trial evaluating the prescribing of drugs to lower high blood pressure. As a clinical research associate at the Stanford University Center for Sleep Sciences and Medicine, Dr. Manugian studied medications to treat restless legs syndrome.
Dr. Manugian presented research to his peers during his residency at the University of Cincinnati Medical Center. He has taught medical students, residents, and physicians about a variety of topics, including alcohol abuse, tick-born illnesses, and managing indigestion.
Dr. Manugian is a member of the American College of Physicians.
